Related Experiment Video
Updated: Jul 13, 2025
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
Dendritic Cell Vaccination in Non-Small Cell Lung Cancer: Remodeling the Tumor Immune Microenvironment
Jensen Abascal1, Michael S Oh1, Elvira L Liclican1
1Division of Pulmonary and Critical Care, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095-1690, USA.
Abstract:
Non-small-cell lung cancer (NSCLC) remains one of the leading causes of death worldwide. While NSCLCs possess antigens that can potentially elicit T cell responses, defective tumor antigen presentation and T cell activation hinder host anti-tumor immune responses. The NSCLC tumor microenvironment (TME) is composed of cellular and soluble mediators that can promote or combat tumor growth. The composition of the TME plays a critical role in promoting tumorigenesis and dictating anti-tumor immune responses to immunotherapy. Dendritic cells (DCs) are critical immune cells that activate anti-tumor T cell responses and sustain effector responses. DC vaccination is a promising cellular immunotherapy that has the potential to facilitate anti-tumor immune responses and transform the composition of the NSCLC TME via tumor antigen presentation and cell-cell communication. Here, we will review the features of the NSCLC TME with an emphasis on the immune cell phenotypes that directly interact with DCs. Additionally, we will summarize the major preclinical and clinical approaches for DC vaccine generation and examine how effective DC vaccination can transform the NSCLC TME toward a state of sustained anti-tumor immune signaling.
Insights
Dendritic cell (DC) vaccination shows promise for treating non-small-cell lung cancer (NSCLC) by enhancing anti-tumor T cell responses. This approach may reshape the tumor microenvironment (TME) to improve immunotherapy effectiveness.
Area of Science:
- Immunology
- Oncology
- Cancer immunotherapy
Background:
- Non-small-cell lung cancer (NSCLC) is a major global health concern.
- Tumor antigen presentation and T cell activation are often impaired in NSCLC, hindering immune responses.
- The tumor microenvironment (TME) significantly influences tumorigenesis and immunotherapy outcomes.
Purpose of the Study:
- To review the immune cell phenotypes within the NSCLC TME that interact with dendritic cells (DCs).
- To summarize preclinical and clinical strategies for generating DC vaccines.
- To examine how DC vaccination can modify the NSCLC TME to promote sustained anti-tumor immunity.
Main Methods:
- Review of existing literature on NSCLC tumor microenvironment composition.
- Analysis of immune cell interactions, particularly with dendritic cells.
- Summary of current and emerging dendritic cell vaccine development approaches.
Main Results:
- Dendritic cells are crucial for activating anti-tumor T cell responses.
- DC vaccination has the potential to alter the NSCLC TME.
- Effective DC vaccination can lead to sustained anti-tumor immune signaling.
Conclusions:
- Dendritic cell vaccination represents a promising cellular immunotherapy for NSCLC.
- This strategy may overcome immune defects within the NSCLC TME.
- DC vaccination could transform the TME to enhance host anti-tumor immunity and improve treatment efficacy.
Related Concept Videos
01:27Tumor Immunotherapy
02:17The Tumor Microenvironment
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...